Credits: Canva
Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.
The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.
The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.
The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.
The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.
The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.
Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."
The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.
However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.
Credit: X.Com
Union Health Minister JP Nadda was admitted to AIIMS Delhi after experiencing uneasiness and underwent tests, including a coronary angiography. The hospital, in a statement, said he is stable and under observation in the cardiology department.
The 65-year-old minister was admitted on August 13 after experiencing uneasiness. He underwent tests, including coronary angiography.
“JP Nadda, Minister of Health and Family Welfare, was evaluated for uneasiness with tests including a coronary angiography on the evening of 13th August 2026. He is currently stable and admitted for observation in the Dept of Cardiology,” AIIMS said in a statement.
Heart problems do not always cause obvious symptoms. While common symptoms include chest pain or pressure, palpitations, and breathing difficulties, reduced blood flow to the heart can sometimes present with subtle signs or no symptoms.
Possible warning signs include:
Coronary angiography is a test used to check the blood vessels supplying the heart for narrowing or blockages.
A thin catheter is usually inserted through an artery in the wrist or groin. Contrast dye is injected, and X-rays are used to visualize the coronary arteries.
Doctors may recommend coronary angiography for:
Regular checkups can help detect heart disease early and monitor risk factors such as:
Regular monitoring can help detect changes early and support timely action to reduce long-term cardiovascular risk.
Regular heart checkups are particularly important for people who:
Depending on individual risk factors, a heart checkup may include:
Additional tests, such as CT coronary angiography or specialized cardiac biomarkers, may be recommended in some cases.
Credit: iStock
Sixty-two deaths in Australia have been reported to the medicines regulator, the Therapeutic Goods Administration (TGA), with suspected associations with GLP-1 medicines, including Ozempic, Wegovy and Mounjaro.
The TGA has also received reports of nearly 3,000 serious adverse events involving these medicines, which are used by hundreds of thousands of Australians, The Herald Sun reported.
Reported adverse reactions include nausea, pancreatitis, suicidal thoughts and a rare eye condition that can cause blindness.
Semaglutide, the active ingredient in Ozempic, used for type 2 diabetes, and Wegovy, approved for weight management, had the highest number of reported deaths with suspected associations.
Other medicines with reported suspected associations include Mounjaro (tirzepatide), Saxenda (liraglutide) and Trulicity (dulaglutide). These drugs are approved to treat type 2 diabetes, obesity, or both.
The reported deaths included:
The TGA states that adverse-event reports alone cannot determine how common a reaction is or be used to directly compare the safety of different medicines. The regulator also said the benefit-risk profile of these medicines remains positive when they are appropriately used for approved indications and in intended patients.
The TGA recently updated warnings for some GLP-1 medicines concerning non-arteritic anterior ischaemic optic neuropathy (NAION), a rare but serious eye condition.
Product warnings across the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class have been updated because of the potential association with the disorder.
NAION can cause permanent visual impairment, including blindness. The TGA notes that no treatment has been shown to improve visual acuity outcomes in people who develop the condition.
GLP-1 RA medicines are prescription drugs used primarily to manage type 2 diabetes and obesity. Thus, the TGA urged patients not to stop treatment on their own.
“These are prescription medicines, so people taking them should discuss benefits, risks and side effects with their healthcare professional rather than stopping or changing treatment based on headlines alone,” the TGA said.
The Australian reports come amid safety monitoring of GLP-1 medicines in other countries. At the same time, clinical evidence has shown important health benefits from some GLP-1 medicines, including reductions in cardiovascular risk and, in certain populations, overall mortality.
Data submitted to the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) showed 82 reported deaths associated with GLP-1 receptor agonists up to January 31, 2025. Of these, 22 were associated with use for weight loss and 60 with use for type 2 diabetes.
In the US, reports in the FDA's FAERS (FDA Adverse Event Reporting System) database have listed 162 deaths associated with Ozempic and Wegovy since 2018.
However, these figures should not be interpreted as confirmed deaths caused by the medicines. Adverse-event reporting systems record suspected associations and cannot by themselves establish a direct causal relationship. Millions of people use GLP-1 medicines, and reported cases can involve other health conditions or factors, including severe complications, dosing errors, and counterfeit or compounded products.
Credit: Instagram
English singer-songwriter Robbie Williams has opened up about being diagnosed with “a little bit of autism” and shared his struggles with intrusive thoughts.
The 52-year-old singer revealed that he had earlier been diagnosed with ADHD, as well as Tourette’s syndrome, the Daily Mail reported.
Speaking at the launch of his clothing brand Hopeium at Flannels, Williams said his autism diagnosis has helped explain some of his behaviors.
“I have ADHD and I just found out I have a bit of autism as well, which I actually f*****g love because it explains so much,” he said.
The British pop icon said he now sees the diagnosis as an explanation for “all the weird” things he does. He also described how ADHD affects his ability to concentrate.
“With the ADHD you can completely and utterly concentrate on something 1000 per cent, but with absolutely everything else, you just cannot do it. Ask my kids,” he said.
The singer said he is “completely and utterly obsessed with creating images and making funny things”.
Williams, who has won a record 18 BRIT Awards, said creativity helps him redirect his thoughts and avoid focusing on things that make him panic or feel scared.
“My brain is incredibly creative, and it can be creative about everything in the world that you panic or are scared about,” he said.
He gave the example of sitting on a plane and having an intrusive thought about possessing telekinetic powers and causing the plane to crash.
He said he has learned to “train my brain to do something better” rather than focusing on worrying thoughts.
Autism is a neurodevelopmental condition that can affect communication, social interaction and behavior. It is a spectrum, meaning symptoms and their severity can vary widely between individuals.
Common characteristics can include repetitive behaviors or interests, difficulty with changes in routine and challenges in social situations.
Williams has also previously spoken about being diagnosed with Tourette’s syndrome. In a recent podcast, he said he had realized that some of the intrusive thoughts he experiences may be connected to Tourette’s, although he does not experience the typical outward tics.
“I've just realized that I have Tourette's, but they don't come out. They are intrusive thoughts that happen,” Williams said.
He also spoke about struggling to fully take in the reaction of audiences, despite performing in front of large crowds.
Williams has said he was diagnosed with ADHD three times because he “forgot” that he had previously been told he had the condition. He first recalled being diagnosed around 2006 after recognizing ADHD symptoms while reading about the condition online.
After his diagnosis, he said he began taking a large number of tablets in the hope that they would “fix” him. He later said his substance misuse escalated, including crushing and snorting the pills.
Williams has faced several addictions and has had multiple stays in rehabilitation since rising to fame in the early 1990s.
ADHD is a neurodevelopmental condition that can involve persistent difficulties with attention, organization and impulse control.
Symptoms can include being easily distracted, forgetfulness, losing things and difficulty maintaining concentration. Some people may also experience restlessness and impulsive behavior.
© 2024 Bennett, Coleman & Company Limited